News

ivWatch Names Kathy Cox as Chief Financial Officer

ivWatch, LLC, inventor of the first and only continuous IV infiltration detection technology, appointments Kathy Cox to Chief Financial Officer. With over 23 years of experience, including 15 years in the medical device manufacturing and healthcare markets, Cox will strengthen the ivWatch leadership team and will provide expertise in driving business growth and operational efficiencies. She will lead the Accounting and Finance functions and report directly to President and Chief Executive Officer Gary Warren.

“Kathy is an exciting addition to our leadership team,” said Gary Warren, President and CEO, ivWatch. “Her strength as a leader at several medical device manufacturers and healthcare companies both privately owned and those held by global publicly-traded parent companies will be invaluable as we continue to grow our company, execute against our long-term strategies, and work to deliver breakthrough technologies to hospitals around the globe.”

“I am thrilled to join ivWatch and work alongside a team of inventors that will continue to improve patient safety and care through relentless innovation,” said Kathy Cox. “The company has a proven track record of putting people first to advance IV therapy and I am excited to bring my knowledge and experience throughout my career to help drive the trajectory of ivWatch and fulfill its mission.”

Prior to joining ivWatch, Cox held a series of executive positions for 12 years within Solesis, an operating division of Michelin and Fenner PLC, including Director/General Manager. She also held the role of Finance Director at Charter Medical and at Xeridiem Medical Devices. Over the course of her career, Cox has developed technical expertise in all aspects of corporate finance, financial planning, and accounting. Her Director/General Manager experience provides her with a strategic business view and commercial mindset that assists in communication of financial data across functional areas of a corporation. She specializes in leading transformative change in teams, processes, and systems to support revenue growth.

Cox, an active CPA since 2000, graduated from Florida State University in Tallahassee, Florida with a B.S. in Accounting.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like